Longevity & AgingPress Release

Cancer survivors giving birth face higher risk of severe maternal complications

A U.S. study of 28 million deliveries finds severe maternal morbidity is higher in past cancer survivors and far higher in women with active cancer.

Wednesday, November 18, 2026 0 views
Published in MedPage Today
Article visualization: Cancer survivors giving birth face higher risk of severe maternal complications

Summary

More women who survived cancer are giving birth, and they face higher rates of serious delivery complications. A U.S. cross-sectional study in JAMA Network Open analyzed national hospital discharge data from 2016 to 2023. Deliveries among past survivors rose from 30.1 to 45.6 per 10,000, while deliveries among women with current cancer stayed flat. Severe maternal morbidity occurred in 11.9 per 1,000 deliveries for past survivors and 48.2 per 1,000 for women with current cancer, versus 6.8 per 1,000 for women without cancer. Inpatient maternal mortality during delivery admission was 14-fold higher for women with current cancer. The data show association, not cause, and come from hospital discharge records. The authors support preconception evaluation and referral to tertiary centers with multidisciplinary teams.

Detailed Summary

Cancer survivorship is a growing part of long-term health, and pregnancy after cancer is an increasingly common issue as treatment outcomes, fertility preservation and assisted reproduction improve. Understanding the risks of childbirth in this group matters for survivors planning families and for the clinicians who care for them.

Researchers led by Koji Matsuo at the University of Southern California analyzed the National Inpatient Sample, which approximates 20% of U.S. hospital discharges, covering 28,360,443 deliveries from 2016 to 2023. About 0.4% were among past cancer survivors, under 0.1% among women with current cancer, and 99.5% among women without cancer. Deliveries among past survivors rose from 30.1 to 45.6 per 10,000 (average annual change 6.3%), while deliveries among current cancer patients stayed roughly flat at 7.0 to 7.4 per 10,000.

Severe maternal morbidity occurred at 6.8 per 1,000 deliveries in women without cancer, 11.9 per 1,000 in past survivors (adjusted IRR 1.45, 95% CI 1.37-1.53) and 48.2 per 1,000 in women with current cancer (adjusted IRR 3.80, 95% CI 3.58-4.04). Inpatient maternal mortality during the delivery admission was 273.0 versus 7.0 per 100,000 deliveries for current cancer versus no cancer (adjusted IRR 14.24). Full-term delivery was less common with current cancer (39.6%) than among past survivors (57.6%). Thyroid cancer, melanoma, breast cancer and lymphoma were the most common prior diagnoses.

The authors say the results support preconception evaluation for survivors and early referral to tertiary centers with multidisciplinary teams, as multiple organizations already recommend. Survivors considering pregnancy may want to discuss timing, treatment history and delivery planning with their oncology and obstetric teams.

Caveats apply. This is observational, cross-sectional work based on discharge codes, so it cannot show that cancer or its treatment caused the complications. It captures only hospital deliveries and does not identify cancer types, treatments or timing in detail in this summary. Absolute risks for past survivors remain low, and the mortality estimate for current cancer rests on few events.

Key Findings

  • Deliveries among past cancer survivors rose from 30.1 to 45.6 per 10,000 from 2016 to 2023; current-cancer deliveries stayed flat.
  • Severe maternal morbidity: 11.9 per 1,000 in past survivors (IRR 1.45) versus 6.8 per 1,000 in women without cancer.
  • Women with current cancer had 48.2 per 1,000 severe morbidity (IRR 3.80) and 14-fold higher inpatient maternal mortality.
  • Full-term delivery occurred in 57.6% of past survivors but only 39.6% of women with current cancer.

Methodology

This is a MedPage Today news report on a cross-sectional study in JAMA Network Open using the National Inpatient Sample (about 20% of U.S. discharges, 28.4 million deliveries, 2016-2023). Outcomes were adjusted incidence rate ratios for severe maternal morbidity. Evidence is observational and based on administrative hospital data.

Study Limitations

Discharge-code data cannot establish causation and lack detail on treatments, remission timing and cancer stage in this summary. The article is truncated, so full morbidity indicators and subgroup results should be checked in the JAMA Network Open paper. Current-cancer estimates, especially mortality, rest on small numbers.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: